Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Exceptional extension!
Enjoy this offer
* See conditions under "Our services"

Valuation: LAMY

Market Cap 1.97Cr 1.73Cr 1.59Cr 1.49Cr 2.8Cr 186.5Cr 2.84Cr 19Cr 7.41Cr 92Cr 7.39Cr 7.23Cr 318.04Cr P/E 2024 *
-
P/E 2025 30.3x
Enterprise Value 1.97Cr 1.73Cr 1.59Cr 1.49Cr 2.8Cr 186.5Cr 2.84Cr 19Cr 7.41Cr 92Cr 7.39Cr 7.23Cr 318.04Cr EV / Sales 2024 *
-
EV / Sales 2025 41,47,73,333x
Free-Float
90%
Yield 2024 *
-
Yield 2025 -
1 day+21.69%
Current month+16.83%
1 month-4.76%
3 months-10.57%
6 months+45.07%
Current year+39.97%
1 month 0.36
Extreme 0.36
0.44
Current year 0.26
Extreme 0.26
0.5
1 year 0.17
Extreme 0.1704
0.94
3 years 0.06
Extreme 0.06
16
5 years 0.06
Extreme 0.06
16
10 years 0.06
Extreme 0.06
16
Manager TitleAgeSince
Chief Executive Officer 61 14/11/2025
Director TitleAgeSince
Director/Board Member 61 14/11/2025
Change 5-day change 1-year change 3-year change Capi.($)
+21.69%0.00%+26.99% - 2.3Cr
+2.64%+6.99%-7.40%+1.15% 4.45TCr
+2.23%+8.26%+323.35%+564.22% 3.6TCr
+1.59%+4.63%+7.23%+54.02% 3.07TCr
+2.07%-4.40%+10.38%-19.99% 2.86TCr
-4.75%-8.02%+5.99%+12.28% 2.3TCr
+4.64%+3.20% - - 1.48TCr
+3.91%+2.57%+53.41%+111.95% 1.35TCr
+2.42%+7.04%+10.86%+19.24% 1.3TCr
+0.13%+3.97%+101.73%+91.70% 1.26TCr
Average +3.60%+1.84%+59.17%+104.32% 2.17TCr
Weighted average by Cap. +1.51%+2.31%+69.96%+122.22%

Financials

2024 2025
Net sales 0.01 0.01 0.01 0.01 0.02 1.09 0.02 0.11 0.04 0.53 0.04 0.04 1.86 0 0 0 0 0.01 0.36 0.01 0.04 0.01 0.17 0.01 0.01 0.61
Net income -25.81T -22.67T -20.89T -19.56T -36.64T -24.45L -37.26T -3L -97.1T -11.99L -96.88T -94.79T -41.69L 51.4T 45.15T 41.6T 38.95T 72.97T 48.69L 74.2T 5L 2L 23.89L 2L 2L 83.03L
Net Debt 56.07T 49.26T 45.39T 42.49T 79.61T 53.12L 80.95T 5L 2L 26.06L 2L 2L 90.58L -
Logo LAMY
LAMY is a clinical stage biotechnology company. The Company is engaged in developing and manufacturing mammalian and plant-derived exosomes using proprietary technologies for nucleic acid loading and targeted delivery to tissues and cells. The platform enables the custom production of exosomes with genetic functionality, capable of selectively targeting specific cells to address diseases with unmet medical needs. The engineered exosomes have demonstrated the potential to target cancer stem cells, the primary drivers of recurrence and metastasis in various cancers, including glioblastoma and pancreatic cancer. Its proprietary manufacturing process utilizes plant-based materials to create exosomes used in various commercial applications, including dermatology and dentistry.
Employees
-
Date Price Change Volume
  1. Stock Market
  2. Stocks
  3. LMMY Stock
-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!